CRISPR-Cas9-Edited TILs: Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer

1. Autologous TILs genetically edited with CRISPR-Cas9 to target intracellular immune checkpoint CISH showed activity in metastatic colorectal cancer.

2. 86% of enrolled patients had successfully manufactured CISH-knockout TIL products.

3. Treatment-related severe adverse events were observed in all patients, with the most common being hematologic events.

4. Stable disease at day 28 was observed in 50% of patients.

5. A patient refractory to anti–PD-1/CTLA-4 therapies had a complete response ongoing at > 21 months. 

Source: The Lancet Oncology